Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282277 · ClinicalTrials.gov registry record · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
A Phase 4 study of Depression and Psychosis, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT05282277: Recruiting Phase 4 study of Depression and Psychosis, sponsored by University of North Carolina, Chapel Hill.
NCT05282277 is a Phase 4 study of Depression and Psychosis that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 103 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05282277, a Phase 4 study of Depression and Psychosis, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic resonance imaging (PET-MR).
Primary Outcome
Characterize reward-related striatal activation measured by fMRI using the Monetary Incentive Delay (MID) task to elicit blood-oxygen-level dependent (BOLD) responses. During MID the task, participants respond to "win" trials by pressing a button on a button box in the MRI as quickly as possible when the see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) response to win trials versus non-win trials. Reactivity is then compared between th
Conditions Studied
Interventions
- DRUG Transdermal Estradiol
- DRUG Micronized Progesterone
- DRUG Matching Placebo Patch
- DRUG Raclopride C11
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT05282277 shows while recruiting
NCT05282277 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 4 interventions - of which Transdermal Estradiol is the first listed.
NCT05282277 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05282277 about?
NCT05282277 is a clinical study titled "Examining the Effects of Estradiol on Neural and Molecular Response to Reward". This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic resonance imaging (PET-MR).
What is the current status of trial NCT05282277?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2022-04-20. Estimated completion is 2026-12-31.
What conditions does trial NCT05282277 study?
This clinical trial studies the following conditions: Depression, Psychosis, Anhedonia.
What interventions are being tested in trial NCT05282277?
The interventions under investigation include: Transdermal Estradiol (DRUG), Micronized Progesterone (DRUG), Matching Placebo Patch (DRUG), Raclopride C11 (DRUG).
Who is sponsoring clinical trial NCT05282277?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05282277 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05282277's enrollment target sits among peer trials
103 322nd of 679 higher than 357 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
-
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
- NCT05865470 · 103 participants · Phase 1
Age-dependent Effects of Smoked and Oral Delta-9-THC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy